Onconetix Statistics
Share Statistics
Onconetix has 44.36M
shares outstanding. The number of shares has increased by -34.85%
in one year.
| Shares Outstanding | 44.36M |
| Shares Change (YoY) | -34.85% |
| Shares Change (QoQ) | 75.35% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 323.63K, so 2.22% of the outstanding
shares have been sold short.
| Short Interest | 323.63K |
| Short % of Shares Out | 2.22% |
| Short % of Float | 2.97% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.09 and the forward
PE ratio is null.
Onconetix's PEG ratio is
0.
| PE Ratio | -0.09 |
| Forward PE | n/a |
| PS Ratio | 57.95 |
| Forward PS | n/a |
| PB Ratio | 0.06 |
| P/FCF Ratio | -0.25 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Onconetix.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.34,
with a Debt / Equity ratio of 0.17.
| Current Ratio | 0.34 |
| Quick Ratio | 0.32 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | -0.27 |
| Debt / FCF | -0.72 |
| Interest Coverage | -53.65 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $4,872.08 |
| Profits Per Employee | $-3,117,474.5 |
| Employee Count | 12 |
| Asset Turnover | 0 |
| Inventory Turnover | 3.26 |
Taxes
| Income Tax | -12.59K |
| Effective Tax Rate | 0.03% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 3.49, so Onconetix's
price volatility has been higher than the market average.
| Beta | 3.49 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 2.22 |
| Relative Strength Index (RSI) | 38.84 |
| Average Volume (20 Days) | n/a |
Income Statement
In the last 12 months, Onconetix had revenue of 58.47K
and earned -37.41M
in profits. Earnings per share was -87.6.
| Revenue | 58.47K |
| Gross Profit | -1.13M |
| Operating Income | -36.03M |
| Net Income | -37.41M |
| EBITDA | -36.71M |
| EBIT | -36.75M |
| Earnings Per Share (EPS) | -87.6 |
Full Income StatementBalance Sheet
The company has 4.55M in cash and 9.89M in
debt, giving a net cash position of -5.33M.
| Cash & Cash Equivalents | 4.55M |
| Total Debt | 9.89M |
| Net Cash | -5.33M |
| Retained Earnings | -56.79M |
| Total Assets | 61.92M |
| Working Capital | -16.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -13.58M
and capital expenditures -55.04K, giving a free cash flow of -13.64M.
| Operating Cash Flow | -13.58M |
| Capital Expenditures | -55.04K |
| Free Cash Flow | -13.64M |
| FCF Per Share | -31.88 |
Full Cash Flow StatementMargins
Gross margin is -1927.93%, with operating and profit margins of -61634.47% and -63986.48%.
| Gross Margin | -1927.93% |
| Operating Margin | -61634.47% |
| Pretax Margin | -64008.02% |
| Profit Margin | -63986.48% |
| EBITDA Margin | -62784.1% |
| EBIT Margin | -61634.47% |
| FCF Margin | -23323.46% |
